Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)

NCT03095651 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus

Interventions

BIOLOGICAL: MK-5160 16 nmol/kg
BIOLOGICAL: MK-5160 32 nmol/kg
BIOLOGICAL: MK-5160 64 nmol/kg
BIOLOGICAL: Glargine 0.4 U/kg
BIOLOGICAL: Placebo to Glargine
BIOLOGICAL: Placebo to MK-5160
DRUG: Dextrose
BIOLOGICAL: Glargine 0.6 U/kg

Sponsor

Merck Sharp & Dohme LLC